# Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Study · id `cardio:ct-nct02437084` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02437084](<https://clinicaltrials.gov/study/NCT02437084>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02437084

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

## Technical summary

Registry record NCT02437084. Allocation not applicable; no masking; primary purpose treatment. Start 2015-05 (actual); primary completion 2020-02 (actual). Results posted on 2021-04-06.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 115 participants (enrolled count; ClinicalTrials.gov record NCT02437084, source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)
- Started: 2015-05 (actual) (ClinicalTrials.gov record NCT02437084, source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)
- Primary completion: 2020-02 (actual) (ClinicalTrials.gov record NCT02437084, source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)
- Completion: 2020-04 (actual) (ClinicalTrials.gov record NCT02437084, source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)
- Results first posted: 2021-04-06 (ClinicalTrials.gov record NCT02437084, source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02437084, source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02437084-2021-04-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
- Condition: Hyperlipidemia
- Condition: Insulin Resistance
- Condition: Type 2 Diabetes
- Intervention (Drug): Atorvastatin
- Lead sponsor: Stanford University
- Lead sponsor class: OTHER
- Collaborator: Doris Duke Charitable Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Stanford University (`cardio:org-stanford-university`)

## Provenance

Content hash: a3d585eb30a3bf5b0d1dec4787793d91751b2ae663d83de2c890876081ad944b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
